Biotech Medics Ne Stock Probability of Future Pink Sheet Price Finishing Over 0.01
| BMCS Stock | USD 0.01 0 16.67% |
Biotech |
Biotech Medics Target Price Odds to finish over 0.01
The tendency of Biotech Pink Sheet price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 0.01 | 90 days | 0.01 | about 98.0 |
Based on a normal probability distribution, the odds of Biotech Medics to move above the current price in 90 days from now is about 98.0 (This Biotech Medics Ne probability density function shows the probability of Biotech Pink Sheet to fall within a particular range of prices over 90 days) .
Given the investment horizon of 90 days Biotech Medics has a beta of 0.81 suggesting as returns on the market go up, Biotech Medics average returns are expected to increase less than the benchmark. However, during the bear market, the loss on holding Biotech Medics Ne will be expected to be much smaller as well. Additionally Biotech Medics Ne has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the Dow Jones Industrial. Biotech Medics Price Density |
| Price |
Predictive Modules for Biotech Medics
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Biotech Medics Ne. Regardless of method or technology, however, to accurately forecast the pink sheet market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the pink sheet market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Biotech Medics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Biotech Medics Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Biotech Medics is not an exception. The market had few large corrections towards the Biotech Medics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Biotech Medics Ne, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Biotech Medics within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.5 | |
β | Beta against Dow Jones | 0.81 | |
σ | Overall volatility | 0 | |
Ir | Information ratio | -0.08 |
Biotech Medics Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Biotech Medics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Biotech Medics Ne can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Biotech Medics Ne generated a negative expected return over the last 90 days | |
| Biotech Medics Ne has high historical volatility and very poor performance | |
| Biotech Medics Ne has some characteristics of a very speculative penny stock | |
| The company has a current ratio of 0.01, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Biotech Medics until it has trouble settling it off, either with new capital or with free cash flow. So, Biotech Medics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Biotech Medics Ne sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Biotech to invest in growth at high rates of return. When we think about Biotech Medics' use of debt, we should always consider it together with cash and equity. | |
| Biotech Medics Ne reported the previous year's revenue of 469.8 K. Net Loss for the year was (603.72 K) with profit before overhead, payroll, taxes, and interest of 408.14 K. | |
| Latest headline from thefly.com: ANI Pharmaceuticals initiated with bullish view at JPMorgan, heres why ANIP |
Biotech Medics Technical Analysis
Biotech Medics' future price can be derived by breaking down and analyzing its technical indicators over time. Biotech Pink Sheet technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Biotech Medics Ne. In general, you should focus on analyzing Biotech Pink Sheet price patterns and their correlations with different microeconomic environments and drivers.
Biotech Medics Predictive Forecast Models
Biotech Medics' time-series forecasting models is one of many Biotech Medics' pink sheet analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Biotech Medics' historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the pink sheet market movement and maximize returns from investment trading.
Things to note about Biotech Medics Ne
Checking the ongoing alerts about Biotech Medics for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Biotech Medics Ne help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| Biotech Medics Ne generated a negative expected return over the last 90 days | |
| Biotech Medics Ne has high historical volatility and very poor performance | |
| Biotech Medics Ne has some characteristics of a very speculative penny stock | |
| The company has a current ratio of 0.01, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Biotech Medics until it has trouble settling it off, either with new capital or with free cash flow. So, Biotech Medics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Biotech Medics Ne sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Biotech to invest in growth at high rates of return. When we think about Biotech Medics' use of debt, we should always consider it together with cash and equity. | |
| Biotech Medics Ne reported the previous year's revenue of 469.8 K. Net Loss for the year was (603.72 K) with profit before overhead, payroll, taxes, and interest of 408.14 K. | |
| Latest headline from thefly.com: ANI Pharmaceuticals initiated with bullish view at JPMorgan, heres why ANIP |
Additional Tools for Biotech Pink Sheet Analysis
When running Biotech Medics' price analysis, check to measure Biotech Medics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biotech Medics is operating at the current time. Most of Biotech Medics' value examination focuses on studying past and present price action to predict the probability of Biotech Medics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Biotech Medics' price. Additionally, you may evaluate how the addition of Biotech Medics to your portfolios can decrease your overall portfolio volatility.